Isomorphic Labs Delays First AI Drug Clinical Trials to End of 2026
Demis Hassabis announced at the World Economic Forum that Isomorphic Labs will push its first clinical trials to late 2026. This marks a one-year delay for the firm.
Insights:
demis hassabis announced on Tuesday at the World Economic Forum in Davos, Switzerland 
CH, that Isomorphic Labs has delayed its first clinical trials until the end of 2026. This announcement represents a one-year pushback from the previous commitment made by demis hassabis of having AI-designed drugs in trials by the end of 2025. This revision signals a slower-than-expected transition from artificial intelligence research to clinical-stage drug candidates.
CH, that Isomorphic Labs has delayed its first clinical trials until the end of 2026. This announcement represents a one-year pushback from the previous commitment made by demis hassabis of having AI-designed drugs in trials by the end of 2025. This revision signals a slower-than-expected transition from artificial intelligence research to clinical-stage drug candidates.
